AD5-TRAIL IN MEN WITH CLINICALLY ORGAN CONFINED PROSTATE CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 前列腺癌的最终治疗仅限于根治性手术或局部或区域性疾病的放射治疗。基因转移技术为前列腺癌新疗法的开发提供了潜力。该项目将使用独特的凋亡剂、肿瘤坏死因子相关的凋亡诱导配体(TRAIL)和以胶原为基础的基质，以增强基因输送系统，以增强免疫活性。该项目的长期目标是开发一种治疗前列腺癌的有效方法。具体地说，治疗包括病毒介导的细胞毒蛋白TRAIL基因进入前列腺，导致前列腺肿瘤细胞凋亡死亡和系统抗肿瘤免疫激活。这些研究将有助于开发最大化基因传递的方法，并确定局部基因转移治疗的毒性和有效性，为未来的研究提供基础，从而为前列腺癌的新治疗方法奠定基础。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Definitive treatment of prostate cancer is limited to radical surgery or radiation therapy for localized or regional disease. Gene transfer technology offers the potential for the development of new therapies for prostate cancer. This project will employ the unique apoptotic agent, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and a collagen-based matrix that enhances gene delivery system to augment immune activation. The long-term objective of the project is to develop an effective treatment for prostate cancer. Specifically, treatment involves the viral-mediated transfer of the gene for the cytotoxic protein TRAIL into the prostate, resulting in prostate tumor cell apoptotic death and activation of systemic antitumor immunity. These studies will help develop methods to maximize gene delivery and determine the toxicity and effectiveness of localized gene transfer therapy which could provide the basis for future studies leading to a new therapeutic approach for prostate cancer.